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Cervical cancer is a virus-induced disease that is caused by the integration of a
human papilloma virus (HPV) DNA into the host’s genome.
1-3 Infection with HPV
causes disruption of the host’s E2 gene, resulting in expression of viral oncogenes,
E6 and E7. The E6 and E7 products inhibit the activities of tumor suppressors, p53
and retinoblastoma protein, respectively. This then eventually leads to the accu-
mulation of damaged DNA and the development of cervical cancer.
4-5 Although
cervical cancer is 1 of the causes of highest mortality in female cancer patients
worldwide, it is a curable disease when diagnosed at an early stage.
6 However,
clear prognostic factors for cervical cancer development are not yet in existence.
Mitochondria, which are cell organelles involved in the processes of cell life and
death and in tumoral transformation, appear to have prominent dysfunction in
cancer cells. Mitochondrial failure induces abnormal ultrastructures, deregulated
metabolism, altered biochemistry and mutation of mitochondrial DNA (mtDNA)
in cells.
7 Mitochondrial molecular chaperones play important roles in protein
transport, protein complex assembly, refolding of misfolded proteins and
triggering of protein degradation by proteosomes.
8-9 Heat shock proteins (HSPs)
are molecular chaperones that are classified into families according to their
molecular weight (i.e., HSP100, HSP90, HSP70, HSP60, and small HPSs). HSPs,
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multiple functions in cellular homeo-stasis including gene
expression regulation, DNA replication, signal transduction,
differentiation, apoptosis, and cellular senescence or
immortalization. They also protect cells from various
stresses such as hypoxia or ischemia, as well as sudden
increases in temperature.
10-12 In normal cells, HSP60 is
mostly localized in the mitochondrial matrix and outer
mitochondrial membrane, constitutively expressed under
normal condition, and induced by heat shock, mitochondrial
damage, and mtDNA depletion.
13,14 Recently, other mole-
cular roles for mammalian HSP60 have been reported. For
example, human HSP60 may trigger apoptosis through
caspase cascade activation by an association between
HSP60/HSP10 complex and pro-caspase-3 inside the
mitochondria, resulting in a subsequent release of the
HSP60 into the cytoplasm.
15
Overexpression of HSP60 has been reported in various
tumors or cancers, such as adrenal Cushing tumors, human
breast, large bowel, bronchial, exocervical, ovarian and
prostate cancers.
16-23 Recently, an upregulation of HSP60 in
preinvasive lesions of the cervix has been shown by immu-
histochemistry.
24 Although HSP60 plays important roles in
various biological events, the exact molecular roles of
HSP60 are still poorly understood, and the relationship
between HSP60 and invasive cervical cancer has not been
reported yet. In this study, we investigated the HSP60
expression in invasive cervical cancer tissues and evaluated
any prognostic significance of HSP60 in cervical cancer
using proteomics, reverse transcriptase polymerase chain
reaction (RT-PCR) and Western blot analyses.
Tissue preparation
The cervical cancer patients were recruited at the outpatient
clinic of the Department of obstetrics and gynecology, Gil
Medical Center, Incheon, Korea. Tissue samples were
collected from 20 cervical cancer patients (mean age, 47.95
± 16.1 years) and 20 normal controls (mean age, 46.80 ±
12.9 years). Cervical biopsies were obtained from patients
with a diagnosis of cervical cancer or uterine myoma as
described previously.
25 The specimens were brought to
clinicopathology department immediately after resection,
and parts of the tissues were subsequently dissected,
divided into several tubes, placed in liquid nitrogen and
stored at -80˚C until analyzed. Cancer samples were
characterized according to International Federation of
Gynecology and Obstetrics (FIGO) stage as fellows: stage
I, 6 case (30%); stage II, 10 case (50%); stage III, 2 case
(10%); and stage IV, 2 case (10%). Histopathology of
cancer samples was evaluated as fellows: squamous cell
carcinoma (SCC), 16 cases (80%); adenocarcinoma, 3 cases
(15%); and malignant mixed müllerian tumor (MMMT), 1
case (5%). Patients with cervical cancer underwent radio-
therapy and/or chemotherapy after biopsy. Normal cervical
tissues came from uterine myoma obtained from women
diagnosed benign condition by Pap smear test. Our study
was approved by the International Review Board on the
experimental studies.
Two-dimensional gel electrophoresis
Biopsy tissues were homogenized in a R/S buffer {9 M
Urea, 2% 3-[(3-Cholamidopropyl) dimethylammonio]-1-
propanesulfonate, 50 mM dithiothreitol (DTT), 0.4%
ampholyte} containing 0.5% each of protease and phospha-
tase inhibitor cocktail, and then ultracentrifuged at 100,000
g for 1 hour (h) at 20˚C. Protein contents of the superna-
tants were determined using a protein assay kit (BioRad,
Hercules, CA, USA), and then the samples were prepared
at 1 mg/350 µL concentration with R/S buffer and stored at
-80˚C. One milligram (mg) of the protein sample was
loaded on an immobilized pH gradient (IPG) strip (pH 4-7)
in PROTEAN IEF CELL (BioRad, Hercules, CA, USA),
and the strip was then covered with mineral oil and rehy-
drated at 50 V for 12 h. Moist wicks were placed at both
ends of the strip to avoid salt contamination while the
protein samples were separated by their isoelectric points
(IP) at 10 KV for 15 h. The IPG strip was then soaked in
equilibration buffer [(375 mM Tris, 6 M Urea, 2% sodium
dodecyl sulfate (SDS), 20% glycerol, 2.5% iodoacetamide)]
for 10 minutes (min), and then the samples which had
previously been separated by IP were separated again on a
2-dimensional SDS-polyacrylamide gel (2D-PAG) [4.0 mL
of 30% acrylamide/Bis, 2.5 mL of 1.5 M Tris-HCl (pH 8.8),
0.1 mL of 10% SDS (w/v), 50  µL of 10% ammonium
persulfate, 5 µL of N,N,N’-tetramethylethylenediamine in
10 mL of 12% 2D-PAG] by their molecular weights at 20
mA/gel for 16 h. Protein spots on 2D-gel were stained with
Coomassie brilliant blue for 24-48 h,
26 de-stained in double
distilled water (ddH2O), and then the stained protein spot
images were analyzed using PDQuest software (BioRad,
Hercules, CA, USA). The protein spots that showed an
increased staining density of up to two fold compared with
their controls were selected for further analysis.
Selected protein spots were individually excised into new
tubes, and the Coomassie blue staining was destained with
50% acetonitrile/25 mM ammonium bicarbonate. Gel slices
containing protein spots were treated with 10 mM DTT at
56˚C for 30 min, and with 55 mM iodoacetamide at room
temperature for 25 min in dark. They were then digested
with trypsin at 37˚C for 16 h with shaking. After pooling
the supernatant into new tubes, peptide samples were dried
completely using SpeedVac system for 4 h. Samples were
dissolved in 50% acetonitrile/ 0.1% trifluoroacetic acid
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MATERIALS AND METHODS(TFA), co-crystallized by mixing with matrix (α-cyano-4-
hydroxy-cinnamic acid saturated with 0.1% TFA/50%
acetonitrile) and loaded on the silcon-coated 96 well
microtiter sample plate (Applied Biosystems, Foster City,
USA). 
Peptides masses were analyzed using Voyager DE
Matrix assisted laser desorption ionization-Time of flight
mass spectrometry (MALDI-TOF) mass spectrometer
(Applied Biosystems, Foster City, USA). Mass spectra
were obtained by averaging 100 to 150 individual laser
shots. Calibration of spectra was performed externally by 2
standard peptide, angiotensin 1 (m/z 1296.6853) and
adrenocorticoptrophic hormone (18-39 clip) (m/z 2465.
1989). A database search for protein sequence for
homology was performed using MS-Fit search algorithm
(http://prospector.ucsf.edu/prospector/4.0.8/html/msfit.htm).
Mass tolerance for the monoisotopic peptide masses were
set to 50 ppm.
Proteomic analysis (i.e., two-dimensional gel electropho-
resis and MALDI-TOF analysis) was carried out twice with
different 2 samples in each group in order to confirm the
peptide profiles analyzed.
Reverse transcription-polymerase chain reaction 
Total RNA was extracted from cervical cancer or normal
tissues with TRIzol reagent (Invitrogen, Carsbad, CA,
USA) according to the manufacturer’s instructions. The
yield of total RNA was determined by measuring the
absorption at 260 nm. Reverse transcription with 1 µg of
total RNA was performed in a final volume of 20 µL using
200 U of Superscript II reverse transcriptase, 0.5 µg oligo
dT12-18 as a primer, 0.5 mM dNTP Mix, 10 mM DTT, and
first strand buffer (Invitrogen, Carsbad, CA, USA). The
mixture of oligo dT12-18 primer, total RNA and diethyl
pyrocarbonate (DEPC) treated ddH2O was heated at 70˚C
for 10 min initially, and other components were then added
and incubated at 42˚C for 1 h. Subsequent incubation at
70˚C for 15 min was carried to inactivate the reverse trans-
criptase. 
To determine the relative levels of HSP60 messenger
RNA  (mRNA), PCR of complementory DNA (cDNA)
was carried out in 20 µL mixture containing 1 µL of cDNA,
10X reaction buffer, 2.5 mM decxynucleoside triphosphate
(dNTP) mix, 6 pmol each of 5’ and 3’ primer, and 1U of G-
Taq DNA polymerase (Bioneer, Daejeon, Korea); Sense:
5’-AGA TGG AGT GGC TGT GCT GA-3’, Antisense: 5’-
CAT CAT AAC CAA CTT CTG AG-3’. The reactions
were started at 94˚C for 5 min and amplified for 30 cycles
of 30 sec at 94˚C, 30 sec at 58˚C and 30 sec at 72˚C. Final
extensions were done for 7 min at 72˚C to compete poly-
merization. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control to confirm equal
loading of the samples. The PCR products were separated
on 2.5% agarose gel using NeSieve GTG agarose (FMC,
Rockland, ME, USA), and analyzed by a digital image
analysis system.
Western blot
For Western blot analysis, cervical tissues were removed
immediately, transferred to LN2 and stored at -80˚C. The
tissues were homogenized in a single detergent lysis buffer
(50 mM Tris, pH 8.0; 150 mM NaCl; 1% Triton X-100;
each of 0.5% protease and phosphatase inhibitor cocktail)
and then centrifuged at 13,000 g for 20 min at 4˚C. The
supernatants transferred into new tubes were measured for
protein contents using a protein assay kit (Biorad , Hercules,
CA, USA), aliquoted at an 5 µg/20 µL concentration in lysis
buffer, and stored at -80˚C. Otherwise, they were used in
the same day. The samples were mixed with loading buffer
(100 mM Tris, pH 6.8; 200 mM DTT; 4% SDS; 20%
glycerol; 0.2% bromophenol blue) at 1 : 1 dilution, boiled
for 5 min, quickly chilled on ice, and then separated on 10%
SDS-polyacrylamide Tris-glycine gels. The proteins were
then transferred onto nitrocellulose membranes (Hybond-C,
Amersham, Bucks, UK) and treated with 5% nonfat dry
milk in 1X phosphate buffered saline-Tween (PBST) (1.46
mM NaH2PO4H2O; 8.05 mM Na2HPO4; 144.72 mM NaCl;
5% Tween 20) overnight at 4˚C. The membranes were
reacted with rabbit anti-HSP60 antibodies (Santa Cruz
Biotechnology, CA, USA) at 1 : 1000 dilution for 1 h, and
then reacted with HRP-conjugated goat anti-rabbit
antibodies (1 : 1000 dilution; Amersham, Bucks, UK) for 1
h at room temperature. The bound antibodies were detected
with chemilu-minescence according to the manufacturer’s
instructions (NEN Life Science, MA, USA), and quantified
using a digital image analysis system.
Statistical analysis
A one-way analysis of variance (ANOVA) was used to
analyze the expression of HSP60 in cervical cancer and
normal tissues. RT-PCR and Western blot data were
subjected to post-hoc Fisher’s protected least significant
difference (PLSD) test and presented by means ± SEM. For
all comparisons, the level of significance was set at p ≤
0.05.
We performed 2D proteomic analysis to evaluate the differ-
ences in protein expression between human cervical cancers
and normal cervical tissues. Protein spots on the 2D gels
were stained with Coomassie blue, and the staining densities
of the spots were analyzed with PDQuest software.
Proteomic analysis was carried out twice with different 2
samples from each group in order to confirm the peptide
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profiles analyzed and one of them is presented (Figs. 1 and
2). In 2D gel analysis of normal cervical tissue, 11 spots
with higher staining densities then cancer tissue were
selected for MALDI-TOF assay (Fig. 1) and identified
(Table 1). Fig. 2 reveals the 2D gel image of the cervical
cancer tissue. Nineteen spots of cervical cancer tissue
samples that showed up to 2 fold increased staining density
compared with their normal control were selected and
identified (Table 2). Specifically, HSP60 protein (Spot 6)
which was overexpressed on cervical cancer gel displayed
dramatically high 98.2% of sequence and corresponded to
its intact molecular size (60 kDa) (Table 2). 
Table 1.List of the Peptides Identified by MALDI-TOF Analysis in Human Normal Cervical Tissue
Spot
Identified proteins
Accession M.W (kDa)* pI
� Sequence
||
No. No. D
� E
§ D E coverage (%)
1
Fragile X mental retardation 
NM_004860 74.54 46 5.9 5.2 30.10
syndrome related protein 2
2 Hypothetical protein XP XM_029836 55.15 40 7.1 4.9 12
3
Keratin 19 type I, 
KRHU9 44.07 41 5 5.2 98
cytoskeletal-human
4 Titin-human S20898 530.92 43 6.6 5.9 96.60
5 Hypothetical protein XP XM_016250 815.94 46 5.4 6.1 79
6 Serine/Threonine kinase 13 NM_003160 32.49 48 9 6.4 30.10
7 Hypothetical protein XP XM_035465 314.76 43 8.9 4.8 43.10
8
Apolipoprotein B precursor; 
NM_000384 517.32 43 6.6 4.7 60.50
apoB-100; apoB-48
9 Chain A, annexin V 1ANW 35.86 31 4.9 5.0 90.90
10 Titin-human XM_038278 1021.6 42 6.5 5.7 45.50
11 Albumin homolog G01747 53.77 50 5.7 6.3 93.30
MALDI-TOF, matrix assisted laser desorption ionization-Time of flight mass spectrometry.
Eleven protein spots selected were individually analyzed. The spot number (Spot No.) corresponds to the position marked on the gel (Fig. 1). Identified
proteins and accession numbers were derived from the MS-Fit search algorithm.
*MW (kDa) represents molecular size of protein.
�pI is an isoelectric point, where the net charge is zero.
�D means the value obtained from the database.
§ E indicates the value estimated from spots on the SDS gel.
‖Sequence coverage (%) is defined as the ratio of the portion of peptide sequence covered by the matched protein to the whole length of peptide
sequence of the spot.
Fig. 1. Proteome pattern of normal cervical tissue. Eleven protein spots on the gel
were marked with arrows. Numbered spots were excised from the normal tissue
gel, in-gel digested with trypsin, and identified by MALDI-TOF assay. The results
are listed in Table 1. MALDI-TOF, matrix assisted laser desorption ionization-Time
of flight mass spectrometry.
Fig. 2. Proteome pattern of cervical cancer tissue. Nineteen protein spots on the
gel were marked with arrows. Numbered spots were excised from the cancer
tissue gel, in-gel digested with trypsin, and identified by MALDI-TOF assay. The
results are listed in Table 2. MALDI-TOF, matrix assisted laser desorption
ionization-Time of flight mass spectrometry.In order to ascertain the increase of HSP60 expression in
cervical cancer tissues, we investigated HSP60 mRNA
expression in cervical cancer and normal cervical tissues
obtained from twenty cancer patients and twenty normal
controls, using semi-quantitative RT-PCR (Fig. 3A). All
samples were quantified and corrected for total input RNA
by normalizing the expression value of GAPDH. Although
HSP60 mRNA was detected in both groups, no statistically
significant differences between cervical cancer and normal
cervical tissues were noted (Fig. 3B). 
To examine the expression levels of HSP60 (60 kDa)
protein, we carried out Western blot analysis in both groups
(Fig. 4A). Anti-actin (43 kDa) was used as an internal
control and expression of HSP60 was normalized by actin
protein. The results obtained from twenty cases of each
group showed that the expression of HSP60 protein in
cervical cancer tissues was significantly increased compared
to cervical normal tissues (p < 0.05) (Fig. 4B). 
The immunohostochemical evaluation of HSP60 in precan-
cer of the cervix has recently been reported,
24 however the
relationship between HSP60 and invasive cervical cancer
has not yet been reported. In this study, we compared
expression levels of HSP60 mRNA or protein between
invasive cervical cancers and cervical normal tissues. 
2D gel proteomic analysis revealed that the expression of
HSP60 was increased in cervical cancer tissues compared to
HSP60 Expression in Cervical Cancer
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Table 2.List of the Peptides Identified by MALDI-TOF Analysis in Human Cervical Cancer Tissue
Spot
Identified proteins
Accession M.W (kDa)* pI
� Sequence
||
No. No. D
� E
§ D E coverage (%)
1 Valosin-containing protein NM_007126 90.16 97 5.1 5.5 97.90
2 Weakly similar to glutathions peroxidase2 4XM_001817 21.19 75 8.6 5.3 7
3 Apo-B 100 precursor X04714 517.02 52 6.7 4.9 35
4
Protein phosphatase 2 reglatory  
NM_006245 70.4      50 8.5    5.2 22.60
delta isoform subunit B(B56)
5 profilaggrin A35938 239.93 56 9 5.4 31
6 Heat shock 60kDa protein 1 (chaperonin) BC010112 60.01 60 5.5 5.6 98.20
7 dnaK-type molecualr chaperone HSPAIL A29160 70.21 68 5.4 5.8 45.50
8 Hypothetical protein XP XM_008578 51.97 50 5.1 5.5 98.20
9 Keratin 19 type I, cytoskeletal-human KRHU9 44.07 42 5 5.4 98.10
10
Apolipoprotein B precursor; apoB-100;
NM_000384 517.32 45 6.6 5.9 93.60
apoB-48
11
Spastic ataxia of charlevoix-saguenay
NM_014363 443.14 30 6.8 4.8 68.60
(sacsin)
12
Ryanodine receptor, (skeletal muscle 
P21817 571.53 32 5.2 4.9 28.30
calcium release channel)
13
Low density lipoprotein-related protein 2; 
NM_004525 545.3 28 4.9 5.9 40.60
megalin
14 Hypothetical protein XP XM_051078 97.84 28 8.3 6.3 35.40
15 Titin-human XM_038278 1021.6 71 6.5 5.5 89.40
16 nebulin NM_004543 776.96 64 9.2 5.8 55.90
17 Keratin 8; keratin-8 NM_002273 53.69 51 5.5 6.0 62.90
18 Albumin homolog G01747 53.77 26 5.7 6.1 50.10
19 NUANCE AF435011 803.61 50 5.3 5.7 73.10
MALDI-TOF, matrix assisted laser desorption ionization-Time of flight mass spectrometry.
Nineteen selected protein spots were individually analyzed. The spot number (Spot No.) corresponds to the position marked on the gel (Fig. 2). Identified
proteins and accession numbers were derived from the MS-Fit search algorithm. 
*MW (kDa) represents the molecular size of protein.
�pI is the isoelectric point, where the net charge is 0. 
�D means the value obtained from the database.
§ E indicates the value estimated from spots on the SDS gel.
‖Sequence coverage (%) is defined as the ratio of the portion of peptide sequence covered by the matched protein to the whole length of peptide
sequence of the spot.
DISCUSSIONnormal tissues (Figs. 1 and 2). It is generally accepted that
DNA damages which cause cancer induce cell cycle arrest,
apoptosis or DNA mutation, resulting from changes in
protein expression. In the present study, protein spots on the
2D gels showed different expression patterns between
cervical cancer and normal cervical tissues, indicating that
the protein expression of normal cervical tissues was
changed by induction or inhibition of genes, and/or by
degeneration or modification of proteins during carcino-
genesis. HSP60 protein of cervical cancer tissues was
markedly elevated, revealed by 2D gel proteomics and
validated by Western blot (Fig. 4). However, there was no
difference in HSP60 mRNA levels between cancer and
normal tissues (Fig. 3). These findings suggest that serial
processes after transcription become important step in
cervical cancer development. Indeed, differences of HSP60
expression were detected in both 2D gels and Western blot,
indicating difference in protein level, but not in mRNA
level. 
It has been known that HSP60 is constitutively expressed
under normal conditions, and its expression is induced by
stressful conditions such as heat shock, mitochondrial
damage, and mtDNA depletion.
14 Although the expression
of HSP60, which is localized in mitochondria, is directly
related to mitochondrial regeneration after cell division or
the increase of mitochondrial activity during normal
conditions, and HSP60 is significantly less expressed in
normal tissues.
13,18,27 On the other hand, the present study
found that HSP60 was significantly overexpressed in
cervical cancer tissues compared to normal cervical tissues.
The overexpression of HSP60 in cervical cancer tissues
suggests that this protein might play a different role in
cervical carcinogenesis. Cappello et al.
22 reported that
elevated expression of HSP60 may be a protective upregu-
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Fig. 3. (A) RT-PCR analysis of HSP60 mRNA in normal (lane 1-8) and cervical
cancer (lane 9-16) tissues. (B) RT-PCR was performed using 1 µgof total RNA and
separated on 2.5% agarose gel. The size of PCR products was 320 base pairs.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal
control to confirm equal loading of the samples. HSP60 mRNA levels were
quantified as a percentage of relative optical density. Results are mean  ± S.E.M.
of 20 samples per group. RT-PCR, reverse transcriptase polymerase chain
reaction; mRNA, messenger RNA; HSP60, heat shock protein.
Fig. 4. (A) Western blot analysis of HSP60 protein in normal controls (lane N1-
N20) and cervical cancers (lane C1-C20) tissues. (B) Anti-actin protein was used
as a control. HSP60 protein levels were quantified as a percentage of relative
optical density. Results are mean ± S.E.M. of 20 samples per group. Expression
level of HSP60 protein in cervical cancer tissues was significantly higher than in
normal tissues (p <  0.05). HSP60, heat shock protein.
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lation against cancer development (i.e. the blockade of
apoptotic machinery that usually takes place during cancer
progression). The involvement of HSP60 in the process of
apoptosis and tumorigenesis is still in dispute. An anti-
apoptotic effect of HSP60 and down-regulation of HSP60
have been reported in cardiac myocytes and bronchial
cancer, respectively.
28,29 On the other hand, overexpression
of HSP60 has been reported in breast and ovarian
carcinomas and myeloid leukemia.
30-32 Moreover, recent
studies showed upregulation of HSP60 during carcino-
genesis of the large bowel and the uterine exocervix.
18,22
Specifically, overexpression of HSP60 has been demon-
strated in early cervical carcinogenesis as well as in prostate
and squamous cervical cancers of both early and advanced
grades.
18,24,27 These results support the possibility that the
expression of HSP60 may play a role as a prognostic factor
of cancer development. By employing immunohisto-
chemistry, Castle et al.
24 showed up-regulation of HSPs in
response to HPV infection and early cervical carcinoge-
nesis, and discussed the role of HSP60 and HSP70 as
surrogate marker for precancer development. However, the
present study found the presence of HPV type 16 in 75% of
our cervical cancer samples, demonstrated by PCR (data not
shown) and they were shown to be invasive cancer stage I
to IV, suggesting that HSP60 expression is also upregulated
in invasive cervical cancer stages as well as precancer stage. 
In conclusion, we compared HSP60 mRNA level and
protein expression in cervical tissues diagnosed as normal
and invasive cervical cancer, and confirmed upregulation
of HSP60 protein in invasive cervical cancer tissues. It
suggests that HSP60 is involved in cervical carcinogenesis,
and can be used as a useful prognostic tool. Since the role
of HSP60 in cancer progression and mechanisms involved
in the regulation of HSP60 expression remain unclear, more
studies are needed to elucidate the relationship between
HSP60 and cancer development. 
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